Literature DB >> 23269227

Deep brain stimulation of the ventral hippocampus restores deficits in processing of auditory evoked potentials in a rodent developmental disruption model of schizophrenia.

Samuel G Ewing1, Anthony A Grace.   

Abstract

Existing antipsychotic drugs are most effective at treating the positive symptoms of schizophrenia but their relative efficacy is low and they are associated with considerable side effects. In this study deep brain stimulation of the ventral hippocampus was performed in a rodent model of schizophrenia (MAM-E17) in an attempt to alleviate one set of neurophysiological alterations observed in this disorder. Bipolar stimulating electrodes were fabricated and implanted, bilaterally, into the ventral hippocampus of rats. High frequency stimulation was delivered bilaterally via a custom-made stimulation device and both spectral analysis (power and coherence) of resting state local field potentials and amplitude of auditory evoked potential components during a standard inhibitory gating paradigm were examined. MAM rats exhibited alterations in specific components of the auditory evoked potential in the infralimbic cortex, the core of the nucleus accumbens, mediodorsal thalamic nucleus, and ventral hippocampus in the left hemisphere only. DBS was effective in reversing these evoked deficits in the infralimbic cortex and the mediodorsal thalamic nucleus of MAM-treated rats to levels similar to those observed in control animals. In contrast stimulation did not alter evoked potentials in control rats. No deficits or stimulation-induced alterations were observed in the prelimbic and orbitofrontal cortices, the shell of the nucleus accumbens or ventral tegmental area. These data indicate a normalization of deficits in generating auditory evoked potentials induced by a developmental disruption by acute high frequency, electrical stimulation of the ventral hippocampus.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23269227      PMCID: PMC3547127          DOI: 10.1016/j.schres.2012.11.023

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  43 in total

1.  Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat.

Authors:  Walter B Hoover; Robert P Vertes
Journal:  Brain Struct Funct       Date:  2007-07-27       Impact factor: 3.270

2.  Sensory gating revisited: relation between brain oscillations and auditory evoked potentials in schizophrenia.

Authors:  Anke Brockhaus-Dumke; Ralf Mueller; Ulrich Faigle; Joachim Klosterkoetter
Journal:  Schizophr Res       Date:  2007-12-21       Impact factor: 4.939

3.  Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars.

Authors:  Francine M Benes; Benjamin Lim; David Matzilevich; Sivan Subburaju; John P Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-22       Impact factor: 11.205

4.  Nucleus accumbens deep brain stimulation produces region-specific alterations in local field potential oscillations and evoked responses in vivo.

Authors:  Clinton B McCracken; Anthony A Grace
Journal:  J Neurosci       Date:  2009-04-22       Impact factor: 6.167

5.  Deep brain stimulation in patients with refractory temporal lobe epilepsy.

Authors:  Paul Boon; Kristl Vonck; Veerle De Herdt; Annelies Van Dycke; Maarten Goethals; Lut Goossens; Michel Van Zandijcke; Tim De Smedt; Isabelle Dewaele; Rik Achten; Wytse Wadman; Frank Dewaele; Jacques Caemaert; Dirk Van Roost
Journal:  Epilepsia       Date:  2007-08       Impact factor: 5.864

6.  Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  J Neurosci       Date:  2007-10-17       Impact factor: 6.167

7.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

8.  Structural abnormalities of the adhesio interthalamica and mediodorsal nuclei of the thalamus in schizophrenia.

Authors:  Mitsuaki Shimizu; Hironobu Fujiwara; Kazuyukki Hirao; Chihiro Namiki; Hidenao Fukuyama; Takuji Hayashi; Toshiya Murai
Journal:  Schizophr Res       Date:  2008-02-19       Impact factor: 4.939

9.  Reduction of prelimbic inhibitory gating of auditory evoked potentials after fear conditioning.

Authors:  Ryan P Mears; Nash N Boutros; Howard C Cromwell
Journal:  Behav Neurosci       Date:  2009-04       Impact factor: 1.912

Review 10.  The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia.

Authors:  Charles B Mikell; Guy M McKhann; Solomon Segal; Robert A McGovern; Matthew B Wallenstein; Holly Moore
Journal:  Stereotact Funct Neurosurg       Date:  2009-06-26       Impact factor: 1.875

View more
  10 in total

1.  Ketamine induced converged synchronous gamma oscillations in the cortico-basal ganglia network of nonhuman primates.

Authors:  Maya Slovik; Boris Rosin; Shay Moshel; Rea Mitelman; Eitan Schechtman; Renana Eitan; Aeyal Raz; Hagai Bergman
Journal:  J Neurophysiol       Date:  2017-05-03       Impact factor: 2.714

Review 2.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

Review 3.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

Review 4.  Brain circuit dysfunction in a distinct subset of chronic psychotic patients.

Authors:  Morris B Goldman
Journal:  Schizophr Res       Date:  2014-07-01       Impact factor: 4.939

5.  Evidence for impaired sound intensity processing during prepulse inhibition of the startle response in a rodent developmental disruption model of schizophrenia.

Authors:  Samuel G Ewing; Anthony A Grace
Journal:  J Psychiatr Res       Date:  2013-08-08       Impact factor: 4.791

6.  Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?

Authors:  Joseph J Taylor; John H Krystal; Deepak C D'Souza; Jason Lee Gerrard; Philip R Corlett
Journal:  Schizophr Res       Date:  2017-09-29       Impact factor: 4.939

7.  Modular, Circuit-Based Interventions Rescue Hippocampal-Dependent Social and Spatial Memory in a 22q11.2 Deletion Syndrome Mouse Model.

Authors:  Julia B Kahn; Russell G Port; Stewart A Anderson; Douglas A Coulter
Journal:  Biol Psychiatry       Date:  2020-05-19       Impact factor: 13.382

8.  Long-term potentiation prevents ketamine-induced aberrant neurophysiological dynamics in the hippocampus-prefrontal cortex pathway in vivo.

Authors:  Cleiton Lopes-Aguiar; Rafael N Ruggiero; Matheus T Rossignoli; Ingrid de Miranda Esteves; José Eduardo Peixoto-Santos; Rodrigo N Romcy-Pereira; João P Leite
Journal:  Sci Rep       Date:  2020-04-28       Impact factor: 4.379

Review 9.  Biomarkers and neuromodulation techniques in substance use disorders.

Authors:  Bettina Habelt; Mahnaz Arvaneh; Nadine Bernhardt; Ivan Minev
Journal:  Bioelectron Med       Date:  2020-02-17

10.  Optogenetic inhibition of ventral hippocampal neurons alleviates associative motor learning dysfunction in a rodent model of schizophrenia.

Authors:  Zheng-Li Fan; Bing Wu; Guang-Yan Wu; Juan Yao; Xuan Li; Ke-Hui Hu; Zhen-Hua Zhou; Jian-Feng Sui
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.